Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Completed

Conditions studied: HCV

In brief

Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection

Key facts

Study ID

NCT02452814

Run by

Hoffmann-La Roche

People needed

8

Starts

2014-05-07

Expected to finish

2017-05-03

Last updated by the study team

2018-02-06

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participated in Study SPC3649-205 (this would include those who completed study SPC3649-205, those who discontinued or terminated the study early for whatever reason (including treatment failure) and those who opted to receive approved therapy for the treatment of HCV infection).

You may not qualify if…

• Those unwilling to provide informed consent for participation in this study.
• Subjects who have received investigational drug therapy after discontinuation, termination, or successful completion of Study SPC3649-205.

Where it is running

• Methodist Transplant Physicians — Dallas, Texas, United States
• Research Specialists of Texas — Houston, Texas, United States
• Fundacion de Investigacion de Diego — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.